Similar articles for PMID: 28575437

Year	Number of Results
1968	1
1970	1
1971	1
1973	1
1976	1
1977	1
1979	1
1983	2
1984	1
1985	1
1987	1
1988	1
1993	1
1994	1
1998	1
2000	1
2001	1
2003	1
2005	2
2007	4
2008	2
2009	1
2010	1
2011	3
2013	3
2014	9
2015	17
2016	15
2017	25
2018	23
2019	7
2020	5
2021	5
2022	2
2023	1
2024	0

1

Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.

Gentile I, Buonomo AR, Maraolo AE, Scotto R, De Zottis F, Di Renzo G, Borgia G. Gentile I, et al. J Antimicrob Chemother. 2017 Sep 1;72(9):2678-2679. doi: 10.1093/jac/dkx172. J Antimicrob Chemother. 2017. PMID: 28575437 No abstract available.

2

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

Kuti JL, Ghazi IM, Quintiliani R Jr, Shore E, Nicolau DP. Kuti JL, et al. Int J Antimicrob Agents. 2016 Sep;48(3):342-3. doi: 10.1016/j.ijantimicag.2016.06.005. Epub 2016 Jul 8. Int J Antimicrob Agents. 2016. PMID: 27451086 No abstract available.

3

Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.

Vickery SB, McClain D, Wargo KA. Vickery SB, et al. Pharmacotherapy. 2016 Oct;36(10):e154-e159. doi: 10.1002/phar.1825. Epub 2016 Sep 1. Pharmacotherapy. 2016. PMID: 27522066

4

Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.

Dietl B, Sánchez I, Arcenillas P, Cuchi E, Gómez L, González de Molina FJ, Boix-Palop L, Nicolás J, Calbo E. Dietl B, et al. Int J Antimicrob Agents. 2018 Mar;51(3):498-502. doi: 10.1016/j.ijantimicag.2017.11.003. Epub 2017 Nov 20. Int J Antimicrob Agents. 2018. PMID: 29158144

5

Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.

Gelfand MS, Cleveland KO. Gelfand MS, et al. Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28. Clin Infect Dis. 2015. PMID: 26021991 No abstract available.

6

Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.

Xipell M, Bodro M, Marco F, Martínez JA, Soriano A. Xipell M, et al. Future Microbiol. 2017 Nov;12:1323-1326. doi: 10.2217/fmb-2017-0018. Epub 2017 Oct 5. Future Microbiol. 2017. PMID: 28980834

7

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).

Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK. Pfaller MA, et al. Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6. Int J Antimicrob Agents. 2018. PMID: 28993143

8

Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.

Castaldo N, Givone F, Peghin M, Righi E, Sartor A, Bassetti M. Castaldo N, et al. J Glob Antimicrob Resist. 2017 Jun;9:100-102. doi: 10.1016/j.jgar.2017.02.012. Epub 2017 May 8. J Glob Antimicrob Resist. 2017. PMID: 28495526

9

Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.

MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L. MacVane SH, et al. Antimicrob Agents Chemother. 2017 Nov 22;61(12):e01183-17. doi: 10.1128/AAC.01183-17. Print 2017 Dec. Antimicrob Agents Chemother. 2017. PMID: 28947473 Free PMC article.

10

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).

Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Sader HS, et al. J Antimicrob Chemother. 2014 Oct;69(10):2713-22. doi: 10.1093/jac/dku184. Epub 2014 Jun 10. J Antimicrob Chemother. 2014. PMID: 24917579

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

131 results

Results by year